Yosef Uziel

TL;DR: The previously proposed classification criteria for Henoch–Schönlein purpura (HSP), childhood polyarteritis nodosa (c-PAN), c-Wegener granulomatosis (C-WG) and c-Takayasu arteritis ( c-TA) are validated.

TL;DR: These two phase 3 studies show the efficacy and safety of canakinumab in systemic JIA with active systemic features, and among the 100 patients who underwent randomization in the withdrawal phase, the risk of flare was lower among patients who continued to receive canakinUMab than among those who were switched to placebo.

TL;DR: Criteria for the classification of macrophage activation syndrome (MAS) in patients with systemic juvenile idiopathic arthritis (JIA) is developed.

TL;DR: The insidious onset of the disease, the delay in diagnosis, the recognition of mixed subtype and the better definition of the other subtypes should influence the efforts in educating trainees and practitioners and help in developing a comprehensive classification system for this syndrome.

TL;DR: Evaluating the response to treatment of autoinflammatory diseases from an international registry and an up-to-date literature review found that colchicine is the treatment of choice for FMF and IL-1 blockade for DIRA and CAPS and Corticosteroids on demand probably represent a valid therapeutic strategy for PFAPA, but also for MKD and TRAPS.